Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ABBV-932 or Placebo Part A | Experimental | Participants will receive oral ABBV-932 or placebo once daily (QD) for 14 days. |
|
| ABBV-932 or Placebo Part B | Experimental | Participants will receive oral ABBV-932 or placebo QD for 14 days. |
|
| ABBV-932 or Placebo Part C | Experimental | Participants will receive oral ABBV-932 or placebo QD 42 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABBV-932 | Drug | Oral Capsule |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of ABBV-932 | Cmax of ABBV-932 | Up to approximately 43 days |
| Time to Cmax (Tmax) of ABBV-932 | Tmax of ABBV-932 | Up to approximately 43 days |
| Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932 | Ctrough of ABBV-932 | Up to approximately 43 days |
| Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine ABBV-932 | AUCtau of ABBV-932 | Up to approximately 43 days |
| Maximum Plasma Concentration (Cmax) of DCAR | Cmax of DCAR | Up to approximately 43 days |
| Time to Cmax (Tmax) of DCAR | Tmax of DCAR | Up to approximately 43 days |
| Observed plasma concentration at the end of a dosing interval (Ctrough) of DCAR | Ctrough of DCAR | Up to approximately 43 days |
| Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine (DCAR) | AUCtau of DCAR |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shanghai Mental Health Center /ID# 273427 | Shanghai | Shanghai Municipality | 200030 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo for ABBV-932 | Drug | Oral Capsule |
|
| Up to approximately 43 days |
| Maximum Plasma Concentration (Cmax) of Didesmethyl-Cariprazine (DDCAR) | Cmax of DDCAR | Up to approximately 43 days |
| Time to Cmax (Tmax) of DDCAR | Tmax of DDCAR | Up to approximately 43 days |
| Observed plasma concentration at the end of a dosing interval (Ctrough) of DDCAR | Ctrough of DDCAR | Up to approximately 43 days |
| Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of DDCAR | AUCtau of DDCAR | Up to approximately 43 days |
| Number of Participants Experiencing Adverse Events | An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. | Up to approximately 75 days |